Literature DB >> 34584221

The E3 ubiquitin ligase TRIM31 plays a critical role in hypertensive nephropathy by promoting proteasomal degradation of MAP3K7 in the TGF-β1 signaling pathway.

Jie Zhang1, Lei Cao1, Xiaohong Wang1, Qian Li1, Meng Zhang6,7, Cheng Cheng1, Liwen Yu1, Fei Xue1, Wenhai Sui1, Shangwen Sun1, Na Li1, Peili Bu1, Bingyu Liu2, Fei Gao1, Junhui Zhen3, Guohai Su4, Cheng Zhang1,4, Chengjiang Gao5, Meng Zhang6,7, Yun Zhang8,9.   

Abstract

Renal fibrosis and inflammation are critical for the initiation and progression of hypertensive renal disease (HRD). However, the signaling mechanisms underlying their induction are poorly understood, and the role of tripartite motif-containing protein 31 (TRIM31), an E3 ubiquitin ligase, in HRD remains unclear. This study aimed to elucidate the role of TRIM31 in the pathogenesis of HRD, discover targets of TRIM31, and explore the underlying mechanisms. Pathological specimens of human HRD kidney were collected and an angiotensin II (AngII)-induced HRD mouse model was developed. We found that TRIM31 was markedly reduced in both human and mouse HRD renal tissues. A TRIM31-/- mice was thus constructed and showed significantly aggravated hypertension-induced renal dysfunction, fibrosis, and inflammation, following chronic AngII infusion compared with TRIM31+/+ mice. In contrast, overexpression of TRIM31 by injecting adeno-associated virus (AAV) 9 into C57BL/6J mice markedly ameliorated renal dysfunction, fibrotic and inflammatory response in AngII-induced HRD relative to AAV-control mice. Mechanistically, TRIM31 interacted with and catalyzed the K48-linked polyubiquitination of lysine 72 on Mitogen-activated protein kinase kinase kinase 7 (MAP3K7), followed by the proteasomal degradation of MAP3K7, which further negatively regulated TGF-β1-mediated Smad and MAPK/NF-κB signaling pathways. In conclusion, this study has demonstrated for the first time that TRIM31 serves as an important regulator in AngII-induced HRD by promoting MAP3K7 K48-linked polyubiquitination and inhibiting the TGF-β1 signaling pathway.
© 2021. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34584221      PMCID: PMC8901735          DOI: 10.1038/s41418-021-00874-0

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   12.067


  47 in total

1.  FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice.

Authors:  Xuebo Pan; Yihui Shao; Fan Wu; Yuan Wang; Rongrong Xiong; Jujia Zheng; Haishan Tian; Baile Wang; Yanfang Wang; Yi Zhang; Zongsheng Han; Aijuan Qu; Haixia Xu; Aihua Lu; Tianxin Yang; Xiaokun Li; Aimin Xu; Jie Du; Zhuofeng Lin
Journal:  Cell Metab       Date:  2018-04-26       Impact factor: 27.287

Review 2.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

Review 3.  Salt, Hypertension, and Immunity.

Authors:  A Justin Rucker; Nathan P Rudemiller; Steven D Crowley
Journal:  Annu Rev Physiol       Date:  2017-11-16       Impact factor: 19.318

Review 4.  Proteinuria should be used as a surrogate in CKD.

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-03-06       Impact factor: 28.314

5.  Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.

Authors:  Kayoko Hosaka; Yunlong Yang; Takahiro Seki; Masaki Nakamura; Patrik Andersson; Pegah Rouhi; Xiaojuan Yang; Lasse Jensen; Sharon Lim; Ninghan Feng; Yuan Xue; Xuri Li; Ola Larsson; Toshio Ohhashi; Yihai Cao
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

6.  PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells.

Authors:  Yuan Xue; Sharon Lim; Yunlong Yang; Zongwei Wang; Lasse Dahl Ejby Jensen; Eva-Maria Hedlund; Patrik Andersson; Masakiyo Sasahara; Ola Larsson; Dagmar Galter; Renhai Cao; Kayoko Hosaka; Yihai Cao
Journal:  Nat Med       Date:  2011-12-04       Impact factor: 53.440

Review 7.  Inflammation, immunity, and hypertensive end-organ damage.

Authors:  William G McMaster; Annet Kirabo; Meena S Madhur; David G Harrison
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

Review 8.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

9.  Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors.

Authors:  Kayoko Hosaka; Yunlong Yang; Takahiro Seki; Qiqiao Du; Xu Jing; Xingkang He; Jieyu Wu; Yin Zhang; Hiromasa Morikawa; Masaki Nakamura; Martin Scherzer; Xiaoting Sun; Yuanfu Xu; Tao Cheng; Xuri Li; Xialin Liu; Qi Li; Yizhi Liu; An Hong; Yuguo Chen; Yihai Cao
Journal:  Nat Commun       Date:  2020-07-24       Impact factor: 14.919

10.  Pericyte-fibroblast transition promotes tumor growth and metastasis.

Authors:  Kayoko Hosaka; Yunlong Yang; Takahiro Seki; Carina Fischer; Olivier Dubey; Erik Fredlund; Johan Hartman; Piotr Religa; Hiromasa Morikawa; Yoko Ishii; Masakiyo Sasahara; Ola Larsson; Giulio Cossu; Renhai Cao; Sharon Lim; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-07       Impact factor: 11.205

View more
  2 in total

1.  Proteostasis Response to Protein Misfolding in Controlled Hypertension.

Authors:  Manuel Teixeira; Dário Trindade; Marisol Gouveia; Roberta Eller-Borges; Sandra Magalhães; Ana Duarte; Miriam Ferreira; Maria I Simões; Maria Conceição; Alexandra Nunes; Ana Gabriela Henriques; Fernando Ribeiro; Sandra I Vieira
Journal:  Cells       Date:  2022-05-19       Impact factor: 7.666

2.  Chinese Classical Music Lowers Blood Pressure and Improves Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats.

Authors:  Jingyuan Li; Zhi Yang; Chunmei Zhang; Yang Hu; Hongxuan Li; Meng Zhang; Peili Bu; Shuangxi Wang; Cheng Zhang; Wenjing Li
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.